The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases

Journal of Clinical Immunology

Volumn 36, Issue , 2016, Pages 95-99

  Sondermann, Peter ^a  

^a SuppreMol GmbH   (Germany)

Author keywords

Fc gamma receptor; Fc R; Fc RIIB; IgG; SM101; SM201; soluble Fc R

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SM 201; UNCLASSIFIED DRUG; PROTEIN BINDING;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; HUMAN; IMMUNOMODULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; IMMUNOSUPPRESSION; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; RECEPTORS, IGG;

EID: 84962177996     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0272-7     Document Type: Article

References (38)

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
2. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014. doi:10.3389/fimmu.2014.00520.
3. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–34.
4. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett. 2005;100:56–67.
5. Pricop L, Redecha P, Teillaud J-L, Frey J, Fridman WH, Sautes-Fridman C, et al. Differential modulation of stimulatory and inhibitory Fc receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166:531–7.
6. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580–92.
7. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14:215–21.
8. de la Salle C, Esposito-Farese M-E, Bieber T, Moncuit J, Morales M, Wollenberg A, et al. Release of soluble FcgammaRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Investig Dermatol. 1992;99:15S–7S.
9. Rappaport EF, Cassel DL, Walterhouse DO, McKenzie SE, Surrey S, Keller MA, et al. A soluble form of the human Fc receptor Fc gamma RIIA: cloning, transcript analysis and detection. Exp Hematol. 1993;21:689–96.
10. Calvo CF, Watanabe S, Mètivier D, Senik A. Human monocyte cell line (U937) releases suppressive IgG-binding factor(s). Eur J Immunol. 1986;16:25–30.
11. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol. 1994;152:1314–22.
12. Fridman WH, Golstein P. Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol. 1974;11:442–55.
13. Ierino FL, Powell MS, McKenzie IF, Hogarth PM. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. J Exp Med. 1993;178:1617–28.
14. Varin N, Sautès C, Galinha A, Even J, Hogarth PM, Fridman WH. Recombinant soluble receptors for the Fcγ portion inhibit antibody productionin vitro. Eur J Immunol. 1989;19:2263–8.
15. Sautès C, Galinha A, Bouchard C, Mazières N, Spagnoli R, Fridman WH. Recombinant soluble Fcγ receptors: production, purification and biological activities. J Chromatogr B Biomed Sci Appl. 1994;662:197–207.
16. Watanabe H, Sherris D, Gilkeson GS. Soluble CD16 in the treatment of murine lupus nephritis. Clin Immunol Immunopathol. 1998;88:91–5.
17. Galon J, Bouchard C, Fridman WH, Sautès C. Ligands and biological activities of soluble Fcγ receptors. Immunol Lett. 1995;44:175–81.
18. Sondermann P, Jacob U. Human Fc gamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem. 1999;380:717–21.
19. Sondermann P, Jacob U, Kutscher C, Frey J. Characterization and crystallization of soluble human Fcγ receptor II (CD32) isoforms produced in insect cells. Biochemistry. 1999;38:8469–77.
20. Maenaka K, van der Merwe PA, Stuart DI, Jones EY, Sondermann P. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem. 2001;276:44,898–904.
21. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human Fcgamma -receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J. 1999;18:1095–103.
22. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc ragment–FcγRIII complex. Nature. 2000;406:267–73.
23. Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc receptor II (CD32). Ann Rheum Dis. 2008;67:154–61.
24. Magnusson SE, Andrén M, Nilsson KE, Sondermann P, Jacob U, Kleinau S. Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb. Clin Immunol. 2008;127:225–33.
25. Iwata H, Pipi E, Möckel N, Sondermann P, Vorobyev A, Beek NV, et al. Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita. J Investig Dermatol. 2015;135:916–9.
26. Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328–43.
27. Tillmanns S, Sondermann P, Schrödter A, Schubert C, Nilius S, Buckel P. Soluble Fc-gamma IIb receptor SM101 as potential therapy in autoimmune diseases – results from a Phase 0/Ia clinical trial in healthy volunteers. Ann Rheum Dis. 2011;70:618.
28. Konstaninova TS, Leonidovna IV, Hellmann A, Kyrcz-Krzemien S, Tillmanns S, Sondermann P, et al. Interim results from a phase Ib/IIa clinical trial with the soluble Fc-gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia. Blood. 2012;120:3388.
29. Tillmanns S, Kolligs C, DP D’C, Doria A, Hachulla E, Voll RE, et al. SM101, a novel recombinant, soluble, human Fc gamma IIb receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. Arthritis Rheum. 2014;66:S1238.
30. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178–84.
31. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
32. Weflen AW, Baier N, Tang Q-J, Van den Hof M, Blumberg RS, Lencer WI, et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell. 2013;24:2398–405.
33. Sondermann P, Oosthuizen V. X-ray crystallographic studies of IgG-FcγR interactions. Biochem Soc Trans. 2002;30:481–6.
34. Chen W, Nordstrom J, Burke S, Shah K, Ciccarone V, Li H, et al. Development of human B-lymphocyte targeted bi-specific DART® molecules for the treatment of autoimmune disorders (THER5P. 830). J Immunol. 2014;192(1 Supplement):200–9.
35. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheum. 2014;66:1153–64.
36. Rieth N, Carle A, Müller M, Meer DT, Direnberger C, Pohl T, et al. Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells. Immunol Lett. 2014;160:145–50.
37. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity. 1999;10:753–60.
38. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8:419–29.